Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Addressing unmet needs in osteosarcoma treatment

Qiyuan Bao • 16 Sep 2024
ESMO 2024
Sarcoma
PROACH

Qiyuan Bao, MD, PhD, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, gives an overview of unmet medical needs in osteosarcoma, a rare subtype of sarcoma. Osteosarcoma often presents with resectable tumors at first relapse, offering potential for a second cure. However, awareness and treatment options remain limited. Improving resectability, survivability, and long-term outcomes for these patients. The Phase II PROACH study (NCT03742193) will hopefully bring novel treatments for these patients. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Qiyuan Bao

BIOVAS: biomarker-driven VEGFR2 inhibition in advanced sarcoma
4:22
BIOVAS: biomarker-driven VEGFR2 inhibition in advanced sarcoma
Qiyuan Bao • 21 Oct 2025
The benefits of biomarker-driven drug development in sarcomas
1:14
The benefits of biomarker-driven drug development in sarcomas
Qiyuan Bao • 21 Oct 2025
Optimizing anti-angiogenic therapies in resectable osteosarcoma
1:54
Optimizing anti-angiogenic therapies in resectable osteosarcoma
Qiyuan Bao • 16 Sep 2024
Key findings on osteosarcoma treatment in the PROACH trial
2:56
Key findings on osteosarcoma treatment in the PROACH trial
Qiyuan Bao • 16 Sep 2024

Related Videos

ctDNA monitoring for recurrence in bone and soft tissue sarcoma
0:58
ctDNA monitoring for recurrence in bone and soft tissue sarcoma
Maggie Zhou • 1 Jun 2026
ctDNA improves detection and prognostication of sarcoma recurrence
0:45
ctDNA improves detection and prognostication of sarcoma recurrence
Maggie Zhou • 1 Jun 2026
Sarcoma highlights at ASCO 2026: SARC-041, PEAK, and RINGSIDE
1:00
Sarcoma highlights at ASCO 2026: SARC-041, PEAK, and RINGSIDE
Maggie Zhou • 1 Jun 2026
Afami-cel T-cell therapy outcomes in advanced metastatic synovial sarcoma
1:52
Afami-cel T-cell therapy outcomes in advanced metastatic synovial sarcoma
Margaret von Mehren • 31 May 2026
The content of VJOncology is intended for healthcare professionals